The integration of the taxane paclitaxel into primary chemotherapy has definitely improved the treatment of advanced ovarian cancer. The GOG 111 study demonstrated that the cisplatin/paclitaxel combination is significantly superior to the former standard, cisplatin/cyclophosphamide, resulting in a markedly improved survival time. In the last years it could be shown that the combination of carboplatin and paclitaxel is equeffective to the combination of cisplatin and paclitaxel. However, with the combination of carboplatin and paclitaxel a distinct improvement of the tolerability of treatment and quality of life is achieved. Thus, it is considered the current treatment standard. Anthracyclines have also demonstrated activity in advanced ovarian cancer. Thus, the Studiengruppe Ovarialkarzinom of the Arbeitsgemeinschaft Gynäkologische Onkologie has initiated a phase III trial to evaluate the benefit of adding epirubicin to the standard carboplatin/paclitaxel combination. Patient accrual for this study has just been finished.

This content is only available via PDF.
© 2000 S. Karger GmbH, Freiburg
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.